HC Wainwright restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $6.00 price objective on the stock.
Context Therapeutics Stock Performance
Shares of CNTX stock opened at $2.08 on Monday. Context Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.75. The firm has a market capitalization of $156.00 million, a PE ratio of -1.56 and a beta of 2.31. The stock has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $1.89.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, sell-side analysts forecast that Context Therapeutics will post -0.31 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
- Five stocks we like better than Context Therapeutics
- How to Capture the Benefits of Dividend Increases
- The Average 401k Balance by Age Explained
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Top Biotech Stocks: Exploring Innovation Opportunities
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.